Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. Krish S. Krishnan, Chairman and CEO, will deliver a company presentation at 12:30 pm ET and engage in investor meetings throughout the day.
A webcast of the presentation will be available starting at 12:30 pm ET on Tuesday, September 10, 2024, accessible through a provided link and subsequently posted on the Investors section of the company's website. This event presents an opportunity for Krystal Biotech to showcase its progress and engage with potential investors in a prominent global investment forum.
Krystal Biotech (NASDAQ: KRYS), una società di biotecnologie in fase commerciale, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright, che si terrà il 10 settembre 2024 a New York. Krish S. Krishnan, Presidente e CEO, presenterà l'azienda alle 12:30 pm ET e parteciperà a incontri con gli investitori durante tutta la giornata.
Un webcast della presentazione sarà disponibile a partire dalle 12:30 pm ET di martedì 10 settembre 2024, accessibile tramite un link fornito e successivamente pubblicato nella sezione Investitori del sito web dell'azienda. Questo evento rappresenta un'opportunità per Krystal Biotech di mostrare i suoi progressi e interagire con potenziali investitori in un importante forum globale per gli investimenti.
Krystal Biotech (NASDAQ: KRYS), una compañía de biotecnología en etapa comercial, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright el 10 de septiembre de 2024 en Nueva York. Krish S. Krishnan, Presidente y CEO, realizará una presentación de la compañía a las 12:30 pm ET y participará en reuniones con inversionistas durante todo el día.
Una transmisión en vivo de la presentación estará disponible a partir de las 12:30 pm ET el martes 10 de septiembre de 2024, accesible a través de un enlace proporcionado y posteriormente publicado en la sección de Inversionistas del sitio web de la compañía. Este evento presenta una oportunidad para que Krystal Biotech muestre su progreso e interactúe con potenciales inversionistas en un destacado foro global de inversiones.
크리스탈 바이오텍 (NASDAQ: KRYS)는 상업 단계의 생명공학 회사로서 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 2024년 9월 10일 뉴욕에서 참석한다고 발표했습니다. 크리시 S. 크리시난, 회장 겸 CEO는 오후 12:30 ET에 회사 발표를 하고 하루 종일 투자자 미팅에 참여할 예정입니다.
발표의 웹캐스트는 2024년 9월 10일 화요일 오후 12:30 ET부터 이용 가능하며, 제공된 링크를 통해 접근할 수 있으며, 이후 회사 웹사이트의 투자자 섹션에 게시될 것입니다. 이 이벤트는 크리스탈 바이오텍이 자신의 발전을 보여주고 주요 글로벌 투자 포럼에서 잠재적 투자자와 소통할 기회를 제공합니다.
Krystal Biotech (NASDAQ: KRYS), une entreprise de biotechnologie en phase commerciale, a annoncé sa participation à la 26ème Conférence Annuelle Globale sur les Investissements de H.C. Wainwright le 10 septembre 2024 à New York. Krish S. Krishnan, Président et CEO, fera une présentation de l'entreprise à 12h30 ET et participera à des réunions avec des investisseurs tout au long de la journée.
Un webinaire de la présentation sera disponible à partir de 12h30 ET le mardi 10 septembre 2024, accessible par un lien fourni et sera ensuite publié dans la section Investisseurs du site web de l'entreprise. Cet événement représente une opportunité pour Krystal Biotech de présenter ses avancées et d'interagir avec des investisseurs potentiels dans un forum d'investissement global et réputé.
Krystal Biotech (NASDAQ: KRYS), ein biotechnologisches Unternehmen in der kommerziellen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright am 10. September 2024 in New York angekündigt. Krish S. Krishnan, Vorsitzender und CEO, wird eine Unternehmenspräsentation um 12:30 Uhr ET halten und den ganzen Tag über an Investorenmeetings teilnehmen.
Ein Webcast der Präsentation wird ab 12:30 Uhr ET am Dienstag, den 10. September 2024, verfügbar sein und über einen bereitgestellten Link zugänglich sein, bevor er anschließend im Investorenbereich der Unternehmenswebsite veröffentlicht wird. Diese Veranstaltung bietet Krystal Biotech die Möglichkeit, ihren Fortschritt zu präsentieren und mit potenziellen Investoren in einem prominenten globalen Investitionsforum in Kontakt zu treten.
- None.
- None.
PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a company presentation at 12:30 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 12:30 pm ET on Tuesday, September 10, 2024 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
When is Krystal Biotech (KRYS) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing Krystal Biotech (KRYS) at the H.C. Wainwright conference?
How can investors access Krystal Biotech's (KRYS) presentation at the H.C. Wainwright conference?
What type of company is Krystal Biotech (KRYS)?
